Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Aceragen
Deal Size : Undisclosed
Deal Type : Acquisition
Idera Pharmaceuticals Acquires Aceragen
Details : The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 (sodium fusidate) and ACG-801, through important 2023 clinical milestones.
Brand Name : ACG-701
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Aceragen
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Tilsotolimod (IMO-2125) has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive immune activation and may, in turn, contribute to tumor suppression ...
Brand Name : IMO-2125
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tilsotolimod,Nivolumab,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Idera Pharmaceuticals Announces Tilsotolimod Updates
Details : Company announced clinical updates regarding IMO-2125 (tilsotolimod), its synthetic Toll-like receptor 9 agonist has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation.
Brand Name : IMO-2125
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 14, 2021
Lead Product(s) : Tilsotolimod,Nivolumab,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AbbVie Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ILLUMINATE-301 is a randomized, global, multi-center, open label Phase 3 trial comparing the efficacy of 8 mg intratumoral tilsotolimod in combination with 3 mg/kg ipilimumab versus 3 mg/kg ipilimumab alone in 481 patients with anti-PD-1 refractory advan...
Brand Name : IMO-2125
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2021
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $20.7 million
Deal Type : Private Placement
Details : The Company plans to use the $10.0 million in cash proceeds to fund the completion of the ongoing ILLUMINATE-301 clinical trial and potential NDA filing of its lead product, tilsotolimod, for the treatment of anti-PD-1 refractory metastatic melanoma.
Brand Name : IMO-2125
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $20.7 million
Deal Type : Private Placement
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
Details : This new coverage expands protection of the first tilsotolimod method-of-use patent, which was directed to methods of treating metastatic melanoma and was issued in November 2019.
Brand Name : IMO-2125
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 28, 2020
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
Details : ILLUMINATE-204 is a multi-center, two-arm phase 1/2 trial in patients with anti-PD-1 refractory advanced melanoma. The phase 1 portion of the trial tested the safety and efficacy of increasing doses of tilsotolimod in combination with either Yervoy®* or...
Brand Name : IMO-2125
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 15, 2020
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Private Placement
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
Details : The Company plans to use the initial proceeds and, if exercised, subsequent proceeds from the financing for the ongoing clinical development of tilsotolimod, its potential NDA filing and commercial launch, and for general corporate purposes.
Brand Name : IMO-2125
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : Tilsotolimod,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Private Placement
Lead Product(s) : Tilsotolimod,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tilsotolimod in combination with Opdivo® (nivolumab) and Yervoy®* (ipilimumab) was generally well tolerated; no patients discontinued treatment due to adverse events (AEs) and none experienced Grade 4 or 5 AEs.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 02, 2020
Lead Product(s) : Tilsotolimod,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tilsotolimod,Ipilimumab,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The combination regimen was generally well tolerated among the 62 patients receiving tilsotolimod at any dose in combination with Yervoy® in the ILLUMINATE-204 clinical trial.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 21, 2020
Lead Product(s) : Tilsotolimod,Ipilimumab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?